- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
DPP-4 Inhibitors Subject of FDA Safety Warning
FDA has warned that the drug class dipeptidyl peptidase-4 (DPP-4) inhibitors may cause joint pain that can be severe and disabling. In a statement, the FDA said said it had issued a "warning and precaution" to all labels in this drug class.
FDA has warned that the drug class dipeptidyl peptidase-4 (DPP-4) inhibitors may cause joint pain that can be severe and disabling. In a statement, the FDA said said it had issued a “warning and precaution” to all labels in this drug class.
The agency stated that patients should not stop taking their DPP-4 inhibitor medications, but should report any joint pain to their physician if it is severe and persistent. Healthcare professionals should consider these medications as a possible cause of severe joint pain and discontinue if appropriate.
DPP-4 inhibitors are prescribed to lower blood sugar levels in adults with type 2 diabetes. This drug class is available as a standalone therapy or as a combination therapy. Approved medications in this class are sitagliptin (Januvia), sitagliptin and metformin (Janumet), sitagliptin and metformin extended release (Janet XR), saxagliptin (Onglyza), saxagliptin and metformin extended release (Kombigllyze XR), linagliptin (Tradjenta), linagliptin and empagliflozin (Glyxambi), linagliptin and metformin (Jentadueto), alogliptin (Nesina), alogliptin and metformin (Kazano), and alogliptin and pioglitazone (Oseni).
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Balancing Care Access and Fragmentation for Better Outcomes in Veterans With Diabetes
April 22nd 2021The authors of a study in the April 2021 issue of The American Journal of Managed Care® discuss the possible reasons behind the link between care fragmentation and hospitalizations in veterans with diabetes, as well as potential opportunities to address disjointed care in the context of the widespread telehealth uptake seen during the COVID-19 pandemic.
Listen
